Cargando…

Cost-Effectiveness Analysis of Fixed-Dose Tiotropium/Olodaterol versus Tiotropium for COPD Patients in China

PURPOSE: Tiotropium/olodaterol (TIO/OLO) fixed-dose combination (FDC) can improve lung function and quality of life for patients with chronic obstructive pulmonary disease (COPD), and is not inferior to other LAMA/LABAs. The aim of this study was to assess the cost-effectiveness of TIO/OLO FDC in pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lan, Ying, Yang, Nan, Wang, Yirong, Yang, Yan, Xu, Min, He, Qin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520256/ https://www.ncbi.nlm.nih.gov/pubmed/37767047 http://dx.doi.org/10.2147/COPD.S425409

Ejemplares similares

Efficacy of tiotropium–olodaterol fixed-dose combination in COPD
por: Derom, Eric, et al.
Publicado: (2016)

Tiotropium/Olodaterol: A Review in COPD
por: Blair, Hannah A.
Publicado: (2019)

Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study
por: Ichinose, Masakazu, et al.
Publicado: (2018)

Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)
por: Buhl, Roland, et al.
Publicado: (2015)

Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study [Corrigendum]
Publicado: (2018)

Dose Determination for a Fixed-Dose Drug Combination: A Phase II Randomized Controlled Trial for Tiotropium/Olodaterol Versus Tiotropium in Patients with COPD
por: Maltais, François, et al.
Publicado: (2019)

Correction to: Tiotropium/Olodaterol: A Review in COPD
por: Blair, Hannah A.
Publicado: (2019)

Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD
por: Muruganandan, Sanjeevan, et al.
Publicado: (2015)

Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD
por: Maltais, François, et al.
Publicado: (2019)

Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium–olodaterol for patients with COPD in the Netherlands
por: van Boven, Job FM, et al.
Publicado: (2016)

Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies
por: Singh, Dave, et al.
Publicado: (2016)

UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD
por: Tebboth, Abigail, et al.
Publicado: (2016)

The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects
por: Derom, Eric, et al.
Publicado: (2019)

Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD
por: Pelaia, Girolamo, et al.
Publicado: (2015)

Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β2-agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study
por: Hoogendoorn, Martine, et al.
Publicado: (2021)

Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD
por: O'Donnell, Denis E., et al.
Publicado: (2017)

Real-world effectiveness of early intervention with fixed-dose tiotropium/olodaterol vs tiotropium in Japanese patients with COPD: a high-dimensional propensity score–matched cohort analysis
por: Muro, Shigeo, et al.
Publicado: (2021)

Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results
por: Hoogendoorn, Martine, et al.
Publicado: (2019)

Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO(®) and OTEMTO(®) Studies
por: Buhl, Roland, et al.
Publicado: (2020)

Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis
por: Miravitlles, Marc, et al.
Publicado: (2017)

Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study
por: Sauer, Rüdiger, et al.
Publicado: (2016)

Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO(®) Trials
por: Rabe, Klaus F., et al.
Publicado: (2020)

Effectiveness and Safety of COPD Maintenance Therapy with Tiotropium/Olodaterol versus LABA/ICS in a US Claims Database
por: Quint, Jennifer K., et al.
Publicado: (2021)

Superiority of tiotropium plus olodaterol in comparison with salmeterol plus fluticasone
por: Tamura, Tomohiro, et al.
Publicado: (2016)

The effect of tiotropium/olodaterol versus fluticasone propionate/salmeterol on left ventricular filling and lung hyperinflation in patients with COPD
por: Herth, Felix, et al.
Publicado: (2020)

Improvement In Self-Reported Physical Functioning With Tiotropium/Olodaterol In Central And Eastern European COPD Patients
por: Valipour, Arschang, et al.
Publicado: (2019)

A comparison of tiotropium/olodaterol vs tiotropium alone in terms of treatment effect for chronic obstructive pulmonary disease: A meta-analysis
por: He, Jie, et al.
Publicado: (2020)

Differential Response to 12 Weeks of Once-Daily Tiotropium/Olodaterol Fixed Dose Combination in Patients with COPD: A Multidimensional Response Profiling in the TORRACTO Study
por: Posthuma, Rein, et al.
Publicado: (2023)

Efficacy of tiotropium/olodaterol on lung volume, exercise capacity, and physical activity
por: Ichinose, Masakazu, et al.
Publicado: (2018)

Effect of tiotropium/olodaterol on sedentary and active time in patients with COPD: post hoc analysis of the VESUTO(®) study
por: Minakata, Yoshiaki, et al.
Publicado: (2019)

Long-term safety of tiotropium/olodaterol in older patients with moderate-to-very-severe COPD in the TONADO® studies
por: Ferguson, Gary T., et al.
Publicado: (2020)

Differences in Real-World Health and Economic Outcomes Among Patients with COPD Treated with Combination Tiotropium/Olodaterol Versus Triple Therapy
por: Palli, Swetha R., et al.
Publicado: (2020)

Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

Role of tiotropium in the treatment of COPD
por: Rice, Kathryn L, et al.
Publicado: (2007)

Assessment of physical functioning and handling of tiotropium/olodaterol Respimat(®) in patients with COPD in a real-world clinical setting
por: Steinmetz, Karl-Otto, et al.
Publicado: (2019)

Effect of tiotropium/olodaterol on sedentary and active time in patients with COPD: post hoc analysis of the VESUTO(®) study [Erratum]
Publicado: (2019)

Health and functional status of tiotropium/olodaterol-treated patients with COPD: results from the AERIAL® non-interventional study
por: Gillissen, Adrian, et al.
Publicado: (2021)

A comparison of tiotropium/olodaterol vs tiotropium alone in terms of treatment effect for chronic obstructive pulmonary disease: A meta-analysis: Retraction
Publicado: (2020)

Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat(®) fixed-dose combination for chronic obstructive pulmonary disease patients in Italy
por: Selya-Hammer, Carl, et al.
Publicado: (2016)

Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol
por: Moretz, Chad, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bil8rg379g6mg55ji3ifs7senk